Biophan Announces Online Availability of Corporate Video on Company's Intellectual Property Portfolio and Biotechnology Advances.

ROCHESTER, N.Y. -- Video Outlines Biophan's Leading Technology in Next-Generation Drug-Delivery, MRI Imaging of Medical Devices, Biothermal Batteries

Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced the online availability of a corporate video outlining the Company's advanced patents in a range of growing multi-billion-dollar biomedical markets, including drug-delivery/drug-elution systems, and the effective Magnetic Resonance Imaging (MRI) of pacemakers and other critical medical devices.

Biophan controls an expanding portfolio of significant patents in nanotechnology and other fields that are enable important improvements in widely-used medical devices, including cardiac pacemakers, vascular and other stents, and numerous surgical tools. The Company is also developing medical applications of unique implantable nanotechnology-based batteries that are powered by body heat, vs. chemicals that wear down, and an ultra-precise, MRI-safe implantable ceramic motor that can be used in a range of applications.

"With the recent trends in increased value for patent portfolios, and patent infringement cases, Biophan is poised to provide an attractive return on investment for the shareholders who helped us build this increasingly broad patent coverage in these important areas of the future of medical devices," stated Michael Weiner, CEO of Biophan.

The video can be viewed at http://www.trilogy-capital.com/tcp/biophan/video.html. There is no cost.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.